Collegium Pharmaceutical (COLL) Downgraded by Zacks Investment Research to “Hold”
Zacks Investment Research cut shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a hold rating in a research note released on Wednesday morning.
According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
A number of other equities research analysts also recently weighed in on the company. Cantor Fitzgerald set a $35.00 price objective on Collegium Pharmaceutical and gave the company a buy rating in a report on Friday, November 30th. BidaskClub raised Collegium Pharmaceutical from a hold rating to a buy rating in a report on Tuesday, November 27th. ValuEngine raised Collegium Pharmaceutical from a sell rating to a hold rating in a report on Thursday, February 28th. SunTrust Banks began coverage on Collegium Pharmaceutical in a report on Tuesday. They set a buy rating and a $22.00 price objective on the stock. Finally, Needham & Company LLC reaffirmed a buy rating and set a $33.00 price objective (down from $35.00) on shares of Collegium Pharmaceutical in a report on Wednesday, January 16th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $28.50.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.65. Collegium Pharmaceutical had a negative return on equity of 41.12% and a negative net margin of 13.95%. The firm had revenue of $73.40 million for the quarter, compared to analyst estimates of $72.71 million. During the same period in the previous year, the company posted ($0.54) earnings per share. The company’s quarterly revenue was up 579.6% compared to the same quarter last year. Analysts anticipate that Collegium Pharmaceutical will post -0.14 EPS for the current fiscal year.
In other news, Director Michael Thomas Heffernan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, February 15th. The stock was sold at an average price of $14.81, for a total value of $370,250.00. Following the transaction, the director now directly owns 259,430 shares of the company’s stock, valued at approximately $3,842,158.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 75,000 shares of company stock worth $1,188,500 over the last three months. 13.87% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Meeder Asset Management Inc. boosted its holdings in shares of Collegium Pharmaceutical by 644.8% in the 4th quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock worth $62,000 after acquiring an additional 3,179 shares in the last quarter. Oregon Public Employees Retirement Fund acquired a new position in shares of Collegium Pharmaceutical in the 4th quarter worth approximately $103,000. Metropolitan Life Insurance Co. NY lifted its holdings in Collegium Pharmaceutical by 412.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 11,124 shares of the specialty pharmaceutical company’s stock worth $191,000 after buying an additional 8,954 shares in the last quarter. Advisory Services Network LLC acquired a new position in Collegium Pharmaceutical during the 4th quarter worth $203,000. Finally, IHT Wealth Management LLC acquired a new position in Collegium Pharmaceutical during the 4th quarter worth $219,000.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Read More: Why is cost of goods sold important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.